3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Advanced Solid Tumor
12
Solid Tumor
5
Nasopharyngeal Carcinoma
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Sarcoma
2
Recurrence
2
Neoplasms
2
Locally Advanced or Metastatic Solid Tumors
2
Liposarcoma
2
Advanced Solid Tumors
2
Advanced Lung Cancer
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Neoplasms
1
Pancreatic Cancer Metastatic
1
PD-1
1
Ovarian Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
Oxaliplatin
16
Irinotecan
12
Fluorouracil
12
Leucovorin
10
Bevacizumab
8
pembrolizumab
7
Cetuximab
7
Capecitabine
7
Nivolumab
5
Gemcitabine
5
Cyclophosphamide
5
fludarabine
4
aldesleukin
4
Panitumumab
4
Folfox protocol
4
oblimersen
3
Interleukin-2
3
selpercatinib
2
poly ICLC
2
labetuzumab
2
dehydroftorafur
2
conatumumab
2
cemiplimab
2
bintrafusp alfa protein, human
2
Tomography, X-Ray Computed
2
Specimen Handling
2
Receptor Protein-Tyrosine Kinases
2
Radiotherapy
2
Levoleucovorin
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colonic Neoplasms
×
toripalimab
×
Clear all
NCT03985891
2020-12-17
JSFOL
Xiangya Hospital of Central South University
Phase 1/2
Unknown
40 enrolled